Genfit (FRA:XUPB) ROCE % : 0.00% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genfit ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genfit's annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

Genfit ROCE % Historical Data

The historical data trend for Genfit's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit ROCE % Chart

Genfit Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-23.79

-41.49

38.57

-9.83

-15.34

Genfit Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Genfit ROCE % Calculation

Genfit's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-23.89	/	( ( (215.54 - 39.37)	+	(173.872 - 38.48) )	/ 2 )
	=	-23.89	/	( (176.17	+	135.392)	/ 2 )
	=	-23.89	/	155.781
	=	-15.34 %

Genfit's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	0	/	( ( (173.872 - 38.48)	+	(194.777 - 36.43) )	/ 2 )
	=	0	/	( ( 135.392	+	158.347 )	/ 2 )
	=	0	/	146.8695
	=	0.00 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Genfit (FRA:XUPB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genfit ROCE % Related Terms

Thank you for viewing the detailed overview of Genfit's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genfit Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (FRA:XUPB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GNFT:USA GNFTF:USA GNFTp:UK 0QT6:UK GNFT:France XUP:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Genfit Headlines

No Headlines